On November 13, 2015 NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor platforms, to improve the lives of patients with cancer reported that data from NLG2101, a global randomized Phase 2 trial testing indoximod in combination with docetaxel or paclitaxel in patients with metastatic breast cancer, will be presented at the San Antonio Breast Cancer Symposium being held December 8-12, 2015 at the Henry B. Gonzalez Convention Center in San Antonio, Texas (Press release, NewLink Genetics, NOV 13, 2015, View Source [SID:1234508239]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation follow:

Abstract Title: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: preliminary data
Abstract Number: P2-11-09
Time: 7:30-9:00 a.m.
Date: Thursday, December 10
Location: Halls A-B
Session Title: Treatment: Immunotherapy (Clinical)
Session Type: Poster